Mark Fereshteh - Publications

Affiliations: 
Duke University, Durham, NC 

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Zhang L, Cherney EC, Zhu X, Lin TA, Gullo-Brown J, Maley D, Johnston-Allegretto K, Kopcho L, Fereshteh M, Huang C, Li X, Traeger SC, Dhar G, Anandam A, Mahankali S, et al. Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy. Acs Medicinal Chemistry Letters. 12: 494-501. PMID 33738077 DOI: 10.1021/acsmedchemlett.1c00014  0.01
2021 Cherney EC, Zhang L, Nara S, Zhu X, Gullo-Brown J, Maley D, Lin TA, Hunt JT, Huang C, Yang Z, Darienzo C, Discenza L, Ranasinghe A, Grubb M, Ziemba T, ... ... Fereshteh M, et al. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. Acs Medicinal Chemistry Letters. 12: 288-294. PMID 33603977 DOI: 10.1021/acsmedchemlett.0c00668  0.04
2020 Nair S, Kumar SR, Paidi VR, Sistla R, Kantheti D, Polimera SR, Thangavel S, Mukherjee AJ, Das M, Bhide RS, Pitts WJ, Murugesan N, Dudhgoankar S, Nagar J, Subramani S, ... ... Fereshteh MP, et al. Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis. Acs Medicinal Chemistry Letters. 11: 1402-1409. PMID 32676146 DOI: 10.1021/Acsmedchemlett.0C00082  0.04
2020 Velaparthi U, Darne CP, Warrier J, Liu P, Rahaman H, Augustine-Rauch K, Parrish K, Yang Z, Swanson J, Brown J, Dhar G, Anandam A, Holenarsipur VK, Palanisamy K, Wautlet BS, ... Fereshteh MP, et al. Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent. Acs Medicinal Chemistry Letters. 11: 172-178. PMID 32071685 DOI: 10.1021/acsmedchemlett.9b00552  0.01
2019 Liu J, Curtin J, You D, Hillerman S, Li-Wang B, Eraslan R, Xie J, Swanson J, Ho CP, Oppenheimer S, Warrack BM, McNaney CA, Nelson DM, Blum J, Kim T, ... Fereshteh M, et al. Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance. Plos One. 14: e0212670. PMID 30913212 DOI: 10.1371/journal.pone.0212670  0.08
2018 Zhang Y, Zhao Y, Tebben AJ, Sheriff S, Ruzanov M, Fereshteh MP, Fan Y, Lippy J, Swanson J, Ho CP, Wautlet BS, Rose A, Parrish K, Yang Z, Donnell AF, et al. Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents. Acs Medicinal Chemistry Letters. 9: 1117-1122. PMID 30429955 DOI: 10.1021/acsmedchemlett.8b00357  0.08
2018 Fan Y, Naglich JG, Koenitzer JD, Ribeiro H, Lippy J, Blum J, Li X, Milburn C, Barnhart B, Zhang L, Fereshteh MP. Miniaturized High-Throughput Multiparameter Flow Cytometry Assays Measuring In Vitro Human Dendritic Cell Maturation and T-Cell Activation in Mixed Lymphocyte Reactions. Slas Discovery : Advancing Life Sciences R & D. 2472555218775409. PMID 29873570 DOI: 10.1177/2472555218775409  0.04
2018 Harikrishnan LS, Warrier J, Tebben AJ, Tonukunuru G, Madduri SR, Baligar V, Mannoori R, Seshadri B, Rahaman H, Arunachalam PN, Dikundwar AG, Fink BE, Fargnoli J, Fereshteh M, Fan Y, et al. Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI). Bioorganic & Medicinal Chemistry. PMID 29422332 DOI: 10.1016/j.bmc.2018.01.014  0.04
2016 Villaume MT, Sella E, Saul G, Borzilleri RM, Fargnoli J, Johnston KA, Zhang H, Fereshteh MP, Dhar TG, Baran PS. Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate. Acs Central Science. 2: 27-31. PMID 27163023 DOI: 10.1021/Acscentsci.5B00345  0.01
2016 Fereshteh MP, Li X, Li S, Fan Y, Zhang R, Farr GA, Kolodin G, Lippy J, Naglich JG, Schieven G, Schweizer L, Zhang L. Development of a Human Whole Blood Screening Platform to Monitor JAK/STAT Signaling Using High-Throughput Flow Cytometry. Journal of Biomolecular Screening. PMID 27142718 DOI: 10.1177/1087057116645095  1
2014 Kotula JW, Sun J, Li M, Pratico ED, Fereshteh MP, Ahrens DP, Sullenger BA, Kovacs JJ. Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. Plos One. 9: e93441. PMID 24736311 DOI: 10.1371/Journal.Pone.0093441  1
2012 Fereshteh M, Ito T, Kovacs JJ, Zhao C, Kwon HY, Tornini V, Konuma T, Chen M, Lefkowitz RJ, Reya T. β-Arrestin2 mediates the initiation and progression of myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 109: 12532-7. PMID 22773819 DOI: 10.1073/Pnas.1209815109  1
2010 Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 17: 388-99. PMID 20385363 DOI: 10.1016/J.Ccr.2010.02.027  1
2009 Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 458: 776-9. PMID 19169242 DOI: 10.1038/Nature07737  1
2008 Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, Dakshanamurthy S, Xu J, Kagan BL, Wellstein A, Riegel AT. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Molecular and Cellular Biology. 28: 6580-93. PMID 18765637 DOI: 10.1128/Mcb.00118-08  1
2008 Fereshteh MP, Tilli MT, Kim SE, Xu J, O'Malley BW, Wellstein A, Furth PA, Riegel AT. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Research. 68: 3697-706. PMID 18483252 DOI: 10.1158/0008-5472.Can-07-6702  1
2007 Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Research. 67: 7256-65. PMID 17671194 DOI: 10.1158/0008-5472.Can-07-1013  1
Show low-probability matches.